Therapeutics News and Research

RSS

Oliver Dowden: New Biothreats Radar will be key to the UK’s fight against future biological threats

A new Biothreats Radar capable of scanning biological risks that pose a threat to the public will be key to the UK's fight and preparation for future pandemics, the Deputy Prime Minister Oliver Dowden has announced today (Monday 12 June).

12 Jun 2023

Keynote speakers of ELRIG Drug Discovery 2023 announced

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focussing on diverse thinking and new perspectives.

10 Jun 2023

Brain network connections linked to anosognosia identified

Anosognosia is a condition in which a patient is unaware of their neurological deficit or psychiatric condition.

9 Jun 2023

Common diabetes drug prevents the development of long COVID, study finds

In a new study published in The Lancet Infectious Diseases, University of Minnesota researchers found that metformin, a drug commonly used to treat diabetes, prevents the development of long COVID.

9 Jun 2023

Shifting towards precision medicine for type 2 diabetes dietary management

Researchers reviewed existing data on the genetic factors and the gene-diet interactions that could alter dietary management of type 2 diabetes.

8 Jun 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Ancient, virus-like protein may contribute to ALS

More than 5,000 people are diagnosed annually with ALS (amyotrophic lateral sclerosis), a fatal, neurodegenerative disease that attacks nerve cells in the brain and spinal cord, gradually robbing people of the ability to speak, move, eat and breathe.

7 Jun 2023

Promising targeted therapy offers new hope to certain patients with advanced pancreatic cancer

A promising new targeted cancer therapy will soon be available to certain patients with advanced pancreatic cancer – from the comfort of their home.

7 Jun 2023

Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.

From Axol Bioscience Ltd 7 Jun 2023

New deep learning model lays the foundation for specialized diagnostic models

Mount Sinai researchers have developed an innovative artificial intelligence (AI) model for electrocardiogram (ECG) analysis that allows for the interpretation of ECGs as language. This approach can enhance the accuracy and effectiveness of ECG-related diagnoses, especially for cardiac conditions where limited data is available on which to train.

7 Jun 2023

Therapeutic nanocarriers engineered from adult skin cells show promise for treating lung injury

Therapeutic nanocarriers engineered from adult skin cells can curb inflammation and tissue injury in damaged mouse lungs, new research shows, hinting at the promise of a treatment for lungs severely injured by infection or trauma.

6 Jun 2023

Two studies seek to understand the drivers of chronic and progressive phase of COVID-19

Early studies of COVID-19 focused on the acute phase of the disease. However, attention has now turned to the long-term consequences of the disease, which are also significant causes of morbidity and mortality.

6 Jun 2023

CN Bio appoints Dr. Samantha Macro as Chief Financial Officer

Key executive appointment provides extensive financial industry experience as the Company implements ambitious global growth strategy.

From CN Bio 6 Jun 2023

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

ELRIG Drug Discovery 2023 at ACC Liverpool (18–19 October) to focus on diverse thinking and new perspectives.

From ELRIG (UK) Ltd. 6 Jun 2023

The universal role of Nsp1: Common mechanisms of translational shutdown by coronaviruses

Researchers investigate Nsp1 from SARS-CoV-2, MERS-CoV, and Bat-Hp-CoV using biophysical, structural, and biochemical assays.

5 Jun 2023

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.

5 Jun 2023

Study provides a treasure trove of information on molecular biology of the immune system

Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases.

5 Jun 2023

Research sheds new light on the genetic architecture of bipolar disorder

Bipolar disorder (BD) is a major psychiatric condition that afflicts about 1% of people. Symptoms of BD include sudden onset of depressive mood with loss of interest which alternates with a manic state of hyperactivity.

5 Jun 2023

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

Lindus Health secures funding to accelerate the use of technology for revolutionizing clinical trials

Ground-breaking trials run by London-based start-up Lindus Health are kicking off to find innovative treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.

5 Jun 2023

Therapeutics News and Research

Oliver Dowden: New Biothreats Radar will be key to the UK’s fight against future biological threats

Keynote speakers of ELRIG Drug Discovery 2023 announced

Brain network connections linked to anosognosia identified

Common diabetes drug prevents the development of long COVID, study finds

Shifting towards precision medicine for type 2 diabetes dietary management

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Ancient, virus-like protein may contribute to ALS

Promising targeted therapy offers new hope to certain patients with advanced pancreatic cancer

Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease

New deep learning model lays the foundation for specialized diagnostic models

Therapeutic nanocarriers engineered from adult skin cells show promise for treating lung injury

Two studies seek to understand the drivers of chronic and progressive phase of COVID-19

CN Bio appoints Dr. Samantha Macro as Chief Financial Officer

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

The universal role of Nsp1: Common mechanisms of translational shutdown by coronaviruses

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

Study provides a treasure trove of information on molecular biology of the immune system

Research sheds new light on the genetic architecture of bipolar disorder

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Lindus Health secures funding to accelerate the use of technology for revolutionizing clinical trials

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News